| Abstract | ADOPT suggests that rosiglitazone, ahead of traditional therapies, can meet patient needs with respect to long-term glycaemic control, yet the recent safety debate, stimulated by retrospective meta-analysis, has seriously affected physician confidence to use it. Other recent evidence, including from a number of long-term outcome studies, does not confirm or exclude a cardiovascular risk signal for rosiglitazone, and evaluation of this data has led EMEA to support continued use of rosiglitazone, albeit with a recommendation not to use in patients with a previous cardiovascular history. Where does this leave us? Rosiglitazone remains the only oral blood glucose lowering agent to have demonstrated nearly 5 years of blood glucose control. Patients earlier in their disease, free of known cardiovascular disease, are just the patients to benefit most from long term glucose target achievement. |
| Authors | Phil Ambery, Bee Pandya
(Affiliation: Cardiovascular and Metabolic Centre of Excellence, GlaxoSmithKline, Middx, United Kingdom. Phil.d.ambery at gsk.com)
|
| Journal | Primary care diabetes
(Prim Care Diabetes)
Vol. 3
Issue 1
Pg. 57-9
(Feb 2009)
ISSN: 1751-9918 [Print] England |
| PMID | 19269912
(Publication Type: Journal Article)
|
| Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Thiazolidinediones
- rosiglitazone
|
| Topics |
- Administration, Oral
- Blood Glucose
(drug effects)
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Evidence-Based Medicine
- Heart Diseases
(chemically induced)
- Humans
- Hypoglycemic Agents
(administration & dosage, adverse effects, therapeutic use)
- Patient Selection
- Practice Guidelines as Topic
- Risk Assessment
- Thiazolidinediones
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|
